Monday, 22 Jan 2018

You are here

Death Rates from Lupus Remain Disproportionately High (Best of 2017)

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

Lupus is a chronic autoimmune disease with limited treatment options. In the 1950s, 5- and 10-year survival rates were less than 50 percent, but those rates jumped to more than 90 percent in the 1980s. The influence of more recent diagnostic and therapeutic developments on lupus mortality in the general population of the United States is unknown. Previous studies of lupus mortality were based primarily on deaths in patient cohorts, which do not capture changes in lupus incidence over time and do not reflect the true burden and trends of lupus mortality in the general population.

Researchers at the David Geffen School of Medicine at UCLA used a national mortality database and census data to identify temporal trends and demographic and regional differences in lupus mortality in the United States over a 46-year period from 1968 through 2013.

They found that the reduction in mortality attributed to lupus was less than the reduction in non-lupus mortality, and the ratio of lupus to non-lupus mortality was about 35 percent higher in 2013 than in 1968. After an initial decrease between 1968 and 1975, lupus mortality increased annually for 24 years, followed by a sustained decrease for 14 years starting in 1999. Changes in lupus incidence over time could partially explain the changing trends; however, significant disparities in lupus mortality among subpopulations were observed.

Mortality rates remained higher among older persons, females, blacks, and Hispanics, as well as in patients who resided in geographic regions in the West and the South. Most interestingly, according to the authors, persons of the same race/ethnicity had differences in lupus mortality, depending on where they lived. White persons living in the South had the highest lupus mortality, whereas non-Whites had the highest lupus mortality in the West.

The study authors stress that it is encouraging that lupus mortality began to decrease in 1999 and that the decrease has been sustained for 14 years, until the end of the study period. They suggest that additional research could help to identify any potentially modifiable risk factors that might inform targeted research and public health programs to address the disparities in lupus mortality rates.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.

Stem Cell Transplant Succeeds in Scleroderma

Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.

Stroke Risk Highest in the First Year of Lupus (Best of 2017)

Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year. 

Registry Efficacy of Rituximab in Refractory SLE

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.

Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's

The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.